Andy W. Tao
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
12
Citations
268
Est. group size
—
Recurring co-author estimate
Active years
24
Publishing since 2002
Andy W. Tao's work spans molecular biology and biochemistry, including studies on cell signaling pathways in cancer (such as the Wnt/β-catenin pathway and the CD177 protein in breast cancer), mass spectrometry-based analytical methods, and lipid-related mechanisms in reproductive health conditions like polycystic ovarian syndrome. The publication record suggests a mix of technique-focused and disease-focused research topics rather than a single narrow specialty.
Publication output has been sparse and irregular over the last decade, with gaps in several years and no more than two papers in any single year.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Lipidomics Reveals Common Mechanisms in Polycystic Ovarian Syndrome, Recurrent Spontaneous Abortion, and Infertility: A Genetic-Based Analysis
International Journal of Women s Health · 2025
- Cancer cell-intrinsic function of CD177 in attenuating β-catenin signaling
Oncogene · 2020
- Abstract 5529: CD177 suppresses breast cancer progression by regulating the canonical WNT β-Catenin pathway
Cancer Research · 2017
- Cancer Research×3
- Oncogene×1
- International Journal of Women s Health×1
- Jin‐Rong Xu
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Kedric L. Milholland
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Hay-Oak Park
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Andrew G. DeMarco
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Aysha H. Osmani
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile